Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis

Company Overview

Fresenius SE & Co. KGaA is a global health care group headquartered in Bad Homburg, Germany. Founded in 1912 by pharmacist Eduard Fresenius, the company has grown through strategic acquisitions and innovation to become one of the world’s leading providers of medical products and services. Over more than a century, Fresenius has expanded its footprint across Europe, the Americas, Asia and Africa, serving patients and healthcare professionals in more than 100 countries.

The company operates through four core business segments. Fresenius Medical Care specializes in dialysis products and services for patients with chronic kidney failure. Fresenius Kabi develops and manufactures clinical nutrition products, infusion therapies and medical devices for hospital and outpatient care. Fresenius Helios is one of Europe’s largest private hospital operators, overseeing more than 130 acute care hospitals and numerous outpatient centers. VAMED provides project management, technical services and solutions for healthcare facilities, supporting clients from planning and construction through operations and maintenance.

Fresenius places a strong emphasis on research and development, investing in innovations ranging from biopharmaceutical manufacturing to digital health solutions. Its leadership team is headed by Chief Executive Officer Dr. Stephan Sturm and Chief Financial Officer Dr. Marcus Both, under the oversight of a Supervisory Board chaired by Georg Funke. With a commitment to improving patient outcomes and increasing access to quality care, the company continues to pursue strategic partnerships and sustainable growth initiatives in key markets worldwide.

Key Stats

• Today's Range: $12.26 to $12.36
• 50-Day Range: $11.72 to $12.85
• 52-Week Range: $7.88 to $12.97
• Volume: 17,809 shs
• Average Volume: 53,729 shs
• Market Capitalization: N/A
• P/E Ratio: 64.77
• Dividend Yield: 1.54%
• Price Target: N/A
• Consensus Rating: Buy

FSNUY Stock Analysis - Frequently Asked Questions

How have FSNUY shares performed this year?

Fresenius SE & Co.'s stock was trading at $8.75 at the beginning of 2025. Since then, FSNUY stock has increased by 40.6% and is now trading at $12.3050.

How were Fresenius SE & Co.'s earnings last quarter?

Fresenius SE & Co. (OTCMKTS:FSNUY) released its earnings results on Wednesday, May, 7th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01. The business earned $5.92 billion during the quarter, compared to analyst estimates of $5.41 billion. Fresenius SE & Co. had a net margin of 1.92% and a trailing twelve-month return on equity of 9.06%.

How do I buy shares of Fresenius SE & Co.?

Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/07/2025
• Ex-Dividend for 6/4 Dividend: 5/27/2025
• Record date for 6/4 Dividend: 5/28/2025
• Dividend Payable: 6/04/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:FSNUY
• CIK: N/A
• Web: www.fresenius.com
• Phone: (496) 172-6080
• Fax: N/A
• Employees: 176,486
• Year Founded: 1912

Profitability

• EPS (Trailing Twelve Months): $0.19
• Trailing P/E Ratio: 64.85
• Forward P/E Ratio: 15.59
• P/E Growth: N/A
• Net Income: $509.67 million
• Net Margins: 1.92%
• Pretax Margin: 7.17%
• Return on Equity: 9.06%
• Return on Assets: 4.17%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.43
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $23.63 billion
• Price / Sales: N/A
• Cash Flow: $1.27 per share
• Price / Cash Flow: 9.68
• Book Value: $9.83 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.75